Jiya Acquisition

Jiya Acquisition was a publicly traded special purpose acquisition company formed to identify and merge with a target in the biopharmaceutical sector. Sponsored by affiliates of Samsara BioCapital, the company completed its IPO in November 2020 and was listed on Nasdaq under the symbol JYAC. It did not operate a therapeutic pipeline or commercial healthcare business of its own; instead, its mandate was to consummate a business combination with a private biopharma company. Jiya Acquisition ultimately failed to complete an initial business combination within the required time period and redeemed its public shares in November 2022. The entity is best understood as a healthcare-focused blank-check vehicle rather than an operating biotech or pharma company.